These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22415492)

  • 1. [Calcimimetics: no competition for surgery in primary hyperparathyroidism].
    Lorenz K
    Chirurg; 2012 Apr; 83(4):384. PubMed ID: 22415492
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of calcimimetics in the treatment of hyperparathyroidism.
    Wüthrich RP; Martin D; Bilezikian JP
    Eur J Clin Invest; 2007 Dec; 37(12):915-22. PubMed ID: 18036025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Basic and clinical aspects of calcimimetics. Treatment of secondary hyperparathyroidism in dialysis patients with calcimimetics].
    Tanaka M; Fukagawa M
    Clin Calcium; 2008 Jan; 18(1):89-93. PubMed ID: 18175877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Calcimimetics].
    Messa P; Como G; Brezzi B
    G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
    Drüeke TB; Ritz E
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of parathyroidectomy versus calcimimetics for secondary hyperparathyroidism and kidney transplantation: a propensity-matched analysis.
    Koh EY; van der Plas WY; Dulfer RR; Pol RA; Kruijff S; Rotmans JI; Appelman-Dijkstra N; Schepers A; de Borst MH; Hoorn EJ; van Ginhoven TM; Nieveen van Dijkum EJM; Vogt L; Engelsman AF;
    Langenbecks Arch Surg; 2020 Sep; 405(6):851-859. PubMed ID: 32778916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: retrospective chart analysis of a prospective database.
    Keutgen XM; Buitrago D; Filicori F; Kundel A; Elemento O; Fahey TJ; Zarnegar R
    Ann Surg; 2012 May; 255(5):981-5. PubMed ID: 22470074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism].
    Hanba Y; Ooura M; Negi S; Shigematsu T
    Clin Calcium; 2008 Jan; 18(1):81-8. PubMed ID: 18175876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
    Lindberg JS
    Kidney Int Suppl; 2005 Jun; (95):S33-6. PubMed ID: 15882311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of calcimimetics in children with normal kidney function.
    VanSickle JS; Srivastava T; Alon US
    Pediatr Nephrol; 2019 Mar; 34(3):413-422. PubMed ID: 29552709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcimimetics and hyperparathyroidism.
    Krebs LJ
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Medical treatment of primary hyperparathyroidism: role of calcimimetics].
    Muñoz Torres M; García Martín A
    Endocrinol Nutr; 2009 Apr; 56 Suppl 1():29-34. PubMed ID: 19627758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Calcimimetics, mechanisms of action and therapeutic applications].
    Ureña P; Legoupil N; de Vernejoul MC
    Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Basic and clinical aspects of calcimimetics. Calcimimetic is indicated for patients with surgically uncontrollable hyperparathyroidism].
    Tominaga Y
    Clin Calcium; 2008 Jan; 18(1):67-71. PubMed ID: 18175874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.
    Esteve Simo V; Moreno-Guzmán F; Martínez Calvo G; Fulquet Nicolas M; Pou Potau M; Macias-Toro J; Duarte-Gallego V; Saurina Sole A; Ramírez-de Arellano Serna M
    Nefrologia; 2015; 35(4):403-9. PubMed ID: 26306967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The calcium receptor and calcimimetics.
    Wada M; Nagano N; Nemeth EF
    Curr Opin Nephrol Hypertens; 1999 Jul; 8(4):429-33. PubMed ID: 10491737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Calcimimetics--a new treatment for hyperparathyroidism?].
    Piecha G; Chudek J; Wiecek A
    Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Surgical and non-surgical management of primary hyperparathyroidism:How do calcimimetics work?].
    Takeuchi Y
    Clin Calcium; 2017; 27(4):553-559. PubMed ID: 28336832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fragility Fractures in Hemodialysis Patients. Calcimimetics and fracture in hemodialysis patients.].
    Goto S
    Clin Calcium; 2018; 28(8):1107-1112. PubMed ID: 30049921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs.
    Wetmore JB; Quarles LD
    Int J Nephrol Renovasc Dis; 2008; 1():5-17. PubMed ID: 21694914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.